Efficacy and Safety of Donidalorsen for Hereditary Angioedema
2024年5月31日 · Donidalorsen, an antisense oligonucleotide, specifically reduces prekallikrein expression. In this phase 3, double-blind, randomized trial, we assigned patients with …
Donidalorsen Under Review for Hereditary Angioedema
2024年11月8日 · Donidalorsen is an investigational ligand-conjugated antisense drug designed to target and reduce the production of prekallikrein (PKK), a precursor of plasma kallikrein. PKK …
2024年7月1日 · Donidalorsen is an investigational medicine for which the safety and efficacy have not been evaluated by any regulatory body. Phase 3 Clinical Development Program
Efficacy and Safety of Donidalorsen for Hereditary Angioedema
2024年7月4日 · Donidalorsen, an antisense oligonucleotide, specifically reduces prekallikrein expression. Methods: In this phase 3, double-blind, randomized trial, we assigned patients …
Ionis drug prevents swelling attacks due to hereditary angioedema …
2024年5月31日 · In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections …
Ionis announces FDA acceptance of New Drug Application for donidalorsen …
2024年11月4日 · Donidalorsen is an investigational RNA-targeted medicine designed to target prekallikrein (PKK), which plays an important role in activating inflammatory mediators …
Inhibition of Prekallikrein for Hereditary Angioedema
2022年3月16日 · Donidalorsen was designed to inhibit the production of plasma prekallikrein by means of ribonuclease (RNase) H1–mediated degradation of plasma prekallikrein messenger …
Donidalorsen for Hereditary Angioedema - The New England …
2024年5月31日 · Management guidelines for patients with hereditary angioedema recommend long-term treatment with prophylactic agents, but breakthrough attacks occur. New research …
The Impact of Donidalorsen Taken Every 8 Weeks in Patients With ...
The phase 2 open-label extension (OLE) study (NCT04307381) of donidalorsen in patients with Type 1/2 hereditary angioedema (HAE) demonstrated a 76% reduction in monthly attack rate …
Donidalorsen: What is it and is it FDA approved? - Drugs.com
2024年11月4日 · Donidalorsen is an investigational RNA-targeted medicine that works by targeting and reducing the production of prekallikrein (PKK). PKK plays an important role in …